Literature DB >> 33823004

Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy.

Leisha A Emens1.   

Abstract

Entities:  

Year:  2021        PMID: 33823004      PMCID: PMC8634411          DOI: 10.1093/jnci/djab068

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

1.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

2.  Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Authors:  Catherine S Grasso; Marios Giannakis; Daniel K Wells; Tsuyoshi Hamada; Xinmeng Jasmine Mu; Michael Quist; Jonathan A Nowak; Reiko Nishihara; Zhi Rong Qian; Kentaro Inamura; Teppei Morikawa; Katsuhiko Nosho; Gabriel Abril-Rodriguez; Charles Connolly; Helena Escuin-Ordinas; Milan S Geybels; William M Grady; Li Hsu; Siwen Hu-Lieskovan; Jeroen R Huyghe; Yeon Joo Kim; Paige Krystofinski; Mark D M Leiserson; Dennis J Montoya; Brian B Nadel; Matteo Pellegrini; Colin C Pritchard; Cristina Puig-Saus; Elleanor H Quist; Ben J Raphael; Stephen J Salipante; Daniel Sanghoon Shin; Eve Shinbrot; Brian Shirts; Sachet Shukla; Janet L Stanford; Wei Sun; Jennifer Tsoi; Alexander Upfill-Brown; David A Wheeler; Catherine J Wu; Ming Yu; Syed H Zaidi; Jesse M Zaretsky; Stacey B Gabriel; Eric S Lander; Levi A Garraway; Thomas J Hudson; Charles S Fuchs; Antoni Ribas; Shuji Ogino; Ulrike Peters
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

3.  Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.

Authors:  Galina G Lagos; Benjamin Izar; Naiyer A Rizvi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03

4.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Authors:  D J McGrail; P G Pilié; N U Rashid; L Voorwerk; M Slagter; M Kok; E Jonasch; M Khasraw; A B Heimberger; B Lim; N T Ueno; J K Litton; R Ferrarotto; J T Chang; S L Moulder; S-Y Lin
Journal:  Ann Oncol       Date:  2021-03-15       Impact factor: 32.976

Review 5.  Predicting immunotherapy response through genomics.

Authors:  Marina Candido Visontai Cormedi; Eliezer M Van Allen; Leandro Machado Colli
Journal:  Curr Opin Genet Dev       Date:  2020-12-08       Impact factor: 5.578

6.  Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker.

Authors:  Elena Fountzilas; Razelle Kurzrock; Henry Hiep Vo; Apostolia-Maria Tsimberidou
Journal:  J Natl Cancer Inst       Date:  2021-04-06       Impact factor: 13.506

7.  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Authors:  Margaretha G M Roemer; Robert A Redd; Fathima Zumla Cader; Christine J Pak; Sara Abdelrahman; Jing Ouyang; Stephanie Sasse; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Stephen Ansell; Kazunobu Kato; Benedetto Farsaci; Anne Sumbul; Philippe Armand; Donna S Neuberg; Geraldine S Pinkus; Azra H Ligon; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

Review 8.  Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review.

Authors:  Josefien W Hommes; Rik J Verheijden; Karijn P M Suijkerbuijk; Dörte Hamann
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

9.  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.

Authors:  Fathima Zumla Cader; Xihao Hu; Walter L Goh; Kirsty Wienand; Jing Ouyang; Elisa Mandato; Robert Redd; Lee N Lawton; Pei-Hsuan Chen; Jason L Weirather; Ron C J Schackmann; Bo Li; Wenjiang Ma; Philippe Armand; Scott J Rodig; Donna Neuberg; X Shirley Liu; Margaret A Shipp
Journal:  Nat Med       Date:  2020-08-10       Impact factor: 53.440

10.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Authors:  Douglas B Johnson; Monica V Estrada; Roberto Salgado; Violeta Sanchez; Deon B Doxie; Susan R Opalenik; Anna E Vilgelm; Emily Feld; Adam S Johnson; Allison R Greenplate; Melinda E Sanders; Christine M Lovly; Dennie T Frederick; Mark C Kelley; Ann Richmond; Jonathan M Irish; Yu Shyr; Ryan J Sullivan; Igor Puzanov; Jeffrey A Sosman; Justin M Balko
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

View more
  3 in total

1.  Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors.

Authors:  Qing Ye; Nancy Lan Guo
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

2.  Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer.

Authors:  Fen Feng; Huake Sun; Zhikun Zhao; Chao Sun; Yongtian Zhao; Hanqing Lin; Jie Yang; Yajie Xiao; Wei Wang; Dongfang Wu
Journal:  J Oncol       Date:  2022-07-13       Impact factor: 4.501

3.  Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.

Authors:  Song-Yang Wu; Ying Xu; Li Chen; Lei Fan; Xiao-Yan Ma; Shen Zhao; Xiao-Qing Song; Xin Hu; Wen-Tao Yang; Wen-Jun Chai; Xiao-Mao Guo; Xi-Zi Chen; Yan-Hui Xu; Xiao-Yu Zhu; Jian-Jun Zou; Zhong-Hua Wang; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Mol Cancer       Date:  2022-03-25       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.